# Cue Biopharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cue-biopharma

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.cuebiopharma.com
- Total disclosed funding: $26M
- Latest round: Seed (Jan 24, 2017)
- Investors on record: 1

## About

Cue Biopharma, Inc. is dedicated to the development of engineered biologics that selectively activate specific immune cells, aiming to restore immune balance for patients suffering from chronic immune-related disorders.Founded in 2015 and headquartered in Boston, US, Cue Biopharma, Inc. focuses on innovative biologics for immune modulation. The company raised USD 30.00 mn in a PIPE funding round with participation from Piper Sandler & Co. and Public Ventures, totaling USD 30.00 mn raised to date. The company has completed four deals, the latest being on December 27, 2017, with the IPO that raised USD 66.2 mn by selling 8.82 million shares at USD 7.5 per share on NASDAQ. The founders Rodolfo Chaparro, Ron Seidel, and Steven Almo have a history of entrepreneurial endeavors, contributing to the company’s strategic direction under CEO Daniel Passeri.Cue Biopharma specializes in engineered biologics that target and activate specific immune cells to treat autoimmune and inflammatory diseases. Their product offerings aim to mimic natural immune signals and are designed for patients with chronic immune-related disorders, benefiting pharmaceutical companies and research institutions primarily in North America and Europe.In 2024, Cue Biopharma reported revenue of USD 9.29 mn alongside an EBITDA of USD -41.07 mn. The company generates revenue through partnerships and public offerings, including collaborations with larger pharmaceutical entities for next-generation treatments, such as their partnership with Boehringer Ingelheim, which reflects their B2B collaboration model.Cue Biopharma plans to expand its product portfolio by developing new biologics targeting autoimmune diseases and launching them by 2025. The company aims to penetrate new markets in Asia and South America by the same year, supported by their recent funding of USD 30.00 mn from the PIPE round. This funding will facilitate research and development efforts to enhance their therapeutic offerings and expand their global reach.

## Funding rounds

- Seed, Jan 24, 2017, $16M — MDB Capital Group
- Seed, Jan 3, 2015, $10M — MDB Capital Group

## Investors

- MDB Capital Group (https://capitalatlas.ai/funds/mdb-capital-group) — Seed